Multibagger Selection: Grok 4.5's picks
Grok 4.5 picked INOD, NRIX, CAPR, PVLA, REPX with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Grok 4.5 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | INOD | — | 72% | — | — |
| 2 | NRIX | — | 68% | — | — |
| 3 | CAPR | — | 65% | — | — |
| 4 | PVLA | — | 62% | — | — |
| 5 | REPX | — | 58% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +1.62% | +1.94% | 1.11x | 0 |
The model's market view
Small and mid-cap equities face mixed conditions with elevated rates pressure but selective AI infrastructure and biotech catalyst windows remain open for asymmetric upside where revenue acceleration and binary events align within the 200M-5B market-cap band.
Why each pick
INOD
Innodata provides AI data engineering, annotation and model-evaluation services with accelerating demand from hyperscalers and enterprise AI platforms. Twelve consecutive quarters of revenue growth, expanding margins and positive free-cash-flow trajectory support operating leverage while valuation remains discounted to recent highs.
NRIX
Nurix Therapeutics advances targeted protein degraders with a major Roche collaboration providing 700M upfront and up to 2.3B milestones. Phase 3 initiation for bexobrutideg in CLL/SLL and multiple partnered programs create near-term clinical and commercial visibility while cash runway extends into 2029.
CAPR
Capricor Therapeutics’ deramiocel (CAP-1002) for Duchenne muscular dystrophy has a PDUFA date of 22 November 2026 after HOPE-3 data supporting upper-limb function. Binary regulatory outcome offers asymmetric upside if approved, with manufacturing and commercial preparations underway.
PVLA
Palvella Therapeutics develops QTORIN rapamycin topical gel for rare genetic skin diseases including microcystic lymphatic malformations. Phase 3 progress and strong institutional ownership support potential commercial inflection if data and regulatory path remain positive.
REPX
Riley Exploration Permian is an oil and gas E&P focused on the Permian Basin with rising production, improving efficiencies and free-cash-flow generation. Production guidance raised and higher oil prices support near-term cash-flow inflection.
Other models on the same run
| Model | Picks |
|---|---|
| Muse Spark 1.1 | LUNR, PL, RDW, SOUN, BBAI |
| DeepSeek | ONDS, CRMD, PRE, RZLV, AXTI |
| GPT-6 | CRMD, EOSE, AMPX, LUNR, SERV |
| Gemini 3 Pro | ACHR, SMR, JOBY, RDW, NNE |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.